Postdoctoral Researcher – van den Brink lab Memorial Sloan Kettering Cancer Center

Company overview

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.

In compliance with applicable State regulatory authorities, COVID-19 vaccination is mandatory for all MSK staff. Staff are considered fully vaccinated upon completion of a primary vaccination series for COVID-19 (i.e., one dose of a single dose vaccine or a final dose of a multi-dose vaccine series). Exceptions from the COVID-19 vaccine requirement are permitted for those who request and receive an approved medical or fully remote exemption.  Requests for medical exemption can take up to two weeks to review. Vaccination or an approved medical exemption is required to start work.

*Staff working at a MSK New Jersey location must be up to date with COVID-19 vaccination, which includes having completed the primary COVID-19 vaccination series and booster once eligible as mandated by New Jersey State. All New Jersey staff not yet eligible for a booster must receive a booster within 3 weeks of becoming eligible as a condition of continued employment at MSK.

Note: Individuals are eligible to receive a COVID-19 booster two months after completion of a primary vaccination series for COVID-19.  Because vaccine-induced immunity can wane over time, MSK continues to strongly urge all staff to get a COVID-19 booster as soon as they become eligible to maintain their protective immunity for a longer period.

Job details

The van den Brink lab is looking for a highly motivated post-doc to work on a project involving novel T cell immunotherapies for multiple myeloma. Our lab focuses on a variety of research topics related to cancer immunotherapy, including hematopoietic stem cell transplantation, graft-versus-host disease, effects of the microbiota on transplant outcomes, immune reconstitution/thymic rejuvenation strategies, and CAR T cell therapy for various malignancies.

The CAR T cell group of the van den Brink lab designs novel CAR T cells targeting hematologic malignancies with the goal of improving T cell activity while reducing toxicities. We study CAR T cell activity in syngeneic mouse models and are currently developing xenograft mouse models. This postdoc position will focus on developing next-generation CAR T cells targeting human myeloma antigens with the goal of translating these CAR T cells into clinical application.

Lab Website**:** https://www.mskcc.org/research/ski/labs/marcel-van-den-brink

Responsibilities**:**

• Human T cell cultures and viral transduction
• In vitro cell proliferation, protein expression, cell viability, immunophenotyping, and cytoxicity assays
• CRISPR/Cas9 and gene transfer
• Generation and maintenance of tumor cell lines and virus producing-packaging lines in culture
• Xenograft models of human myeloma in mice
• Mouse handling, injection, and harvesting tissues
• Multi-color flow cytometry
• Molecular cloning of CAR constructs

The ideal candidate should have:

• PhD, MD/PhD, or MD completed in cancer immunology, immunotherapy, T cell biology, cell engineering, or related field
• Excellent verbal and written communication skills
• Solid publication record
• Experience with human T cell culture and retroviral/lentiviral transduction methods or non-viral vector modification.
• Experience with multi-color flow cytometry panels is preferred
• Experience with mouse handling and procedures is advantageous, but not required

If you have any questions about this job opportunity, please contact:

Marcel van den Brink

[email protected]

Salary: $55,439-$74,263